- Localization of Oncogenic Osteomalacia by Systemic Venous Sampling of Fibroblast Growth Factor 23
-
Lee JY, Park HS, Han S, Lim JK, Hong N, Park SI, Rhee Y
- KMID: 2418934
- Yonsei Med J.
- 2017 Sep;58(5):981-987.
- doi: 10.3349/ymj.2017.58.5.981
PURPOSE: Tumor-induced osteomalacia (TIO) is characterized by hypophosphatemia caused by a phosphaturic mesenchymal tumor. While surgical resection of the tumor leads to a cure, identification of the responsible tumor is... -
- CITED
-
- Close
- SHARE
-
- Close
- Association between Serum Fibroblast Growth Factor 21 and Coronary Artery Disease in Patients with Type 2 Diabetes
-
Kim WJ, Kim SS, Lee HC, Song SH, Bae MJ, Yi YS, Jeon YK, Kim BH, Kim YK, Kim IJ
- KMID: 2155471
- J Korean Med Sci.
- 2015 May;30(5):586-590.
- doi: 10.3346/jkms.2015.30.5.586
The aim of this study was to evaluate the association of plasma fibroblast growth factor (FGF)-21 with angiographically significant coronary artery disease (CAD) in patients with type 2 diabetes mellitus.... -
- CITED
-
- Close
- SHARE
-
- Close
- Serum Fibroblast Growth Factor 21 and New-Onset Metabolic Syndrome: KoGES-ARIRANG Study
-
Choi JR, Kim JY, Park IH, Huh JH, Kim KW, Cha SK, Park KS, Sohn JH, Park JT, Koh SB
- KMID: 2418793
- Yonsei Med J.
- 2018 Mar;59(2):287-293.
- doi: 10.3349/ymj.2018.59.2.287
PURPOSE: Fibroblast growth factor 21 (FGF21) is a crucial metabolic regulator, with multiple favorable effects on glucose homeostasis and lipid metabolism. Since serum FGF21 level has been implicated as a... -
- CITED
-
- Close
- SHARE
-
- Close
